Skip to main content

Advertisement

SpringerLink
Log in

Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Systemic therapy improves the survival and quality of life of patients with advanced stage non-small cell lung cancer (NSCLC). Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementation group-1 (ERCC1) in locally advanced NSCLC patients that received cisplatin-based chemotherapy. Clinical data concerning 80 patients with histopathologically confirmed non-small cell lung cancer who are planned to receive cisplatin-based adjuvant chemotherapy were collected. The protein expression levels for ERCC1 are immunohistochemical examined in 80 patients. The relationship between the ERCC1 protein expression level and the clinical outcomes of the patients is then observed. The 3-year survival rate and median survival time of stage III NSCLC received chemotherapy with/without concurrent chemoradiotherapy were 20 % and 10 months, respectively. Survival of patients with ERCC1-negative tumors was significantly longer than those with ERCC1-positive tumors (p = 0.0001). Prognostic factors with overall survival were performance status, cigarette smoking, stage, weight loss and ERCC1. While as regard progression-free survival prognostic factors were stage, weight loss, ERCC1 and degree of positivity of ERCC1 progression. It was found that ERCC1 protein expression might play an important role in the prognosis of locally advanced NSCLC patients treated with cisplatin-based adjuvant chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.

    Article  PubMed  Google Scholar 

  2. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European organization for research and treatment of cancer lung cancer group–EORTC 08975. J Clin Oncol. 2003;21:3909–17.

    Article  CAS  PubMed  Google Scholar 

  3. Yau T, Ashley S, Popat S, et al. Time and chemotherapy treatment trends in the treatment of elderly patients (age >/=70 years) with small cell lung cancer. Br J Cancer. 2006;94:18–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847–57.

    Article  CAS  PubMed  Google Scholar 

  5. Friedberg EC. DNA damage and repair. Nature. 2003;421:436–40.

    Article  PubMed  Google Scholar 

  6. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193–204.

    Article  CAS  PubMed  Google Scholar 

  7. Phillips DH. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis. 2002;23:1979–2004.

    Article  CAS  PubMed  Google Scholar 

  8. Lababede O, Meziane M, Rice T. Seventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagrams. Chest. 2011;139(1):183–9.

    Article  PubMed  Google Scholar 

  9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  PubMed  Google Scholar 

  10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  CAS  PubMed  Google Scholar 

  11. Seyhan EC, Altın S, Cetinkaya E, et al. Prognostic significance of ERCC1 expression in resected non-small cell lung carcinoma. Ann Thorac Cardiovasc Surg. 2011;17:110–7.

    Article  PubMed  Google Scholar 

  12. American cancer society: Cancer facts and figures 2014. Atlanta, Ga: American Cancer Society, 2014.

  13. Yau T, Ashley S, Popat S, et al. Time and chemotherapy treatment trends in the treatment of elderly patients (age >/= 70 years) with small cell lung cancer. Br J Cancer. 2009;94:18–21.

    Article  Google Scholar 

  14. Jiang J, Liang X, Zhou X, et al. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep. 2012;39(6):6933–42.

    Article  CAS  PubMed  Google Scholar 

  15. Li J, Li ZN, Yu LC, et al. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer. 2010;69(1):116–22.

    Article  PubMed  Google Scholar 

  16. Fujii T, Toyooka S, Ichimura K, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer. 2008;59:377–84.

    Article  PubMed  Google Scholar 

  17. Wang J, Zhang Q, Zhang H, et al. Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy. Zhongguo Fei Ai Za Zhi. 2010;13(4):337–41.

    CAS  PubMed  Google Scholar 

  18. Simon GR, Schell MJ, Begum M. Early indication of survival benefit from ERCC1 and RRM1 tailored chemotherapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC). Evidence from an individual patient analysis. Cancer. 2012;118(9):2525–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Olaussen KA, Dunant A, Fouret P, IALT Bio Investigators, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.

    Article  CAS  PubMed  Google Scholar 

  20. Leng XF, Chen MW, Xian L, et al. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res. 2012;31(1):25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Vokes EE, Herndon JE 2nd, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002;20:4191–8.

    Article  CAS  PubMed  Google Scholar 

  22. Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005;16:1069–75.

    Article  CAS  PubMed  Google Scholar 

  23. Huber RM, Flentje M, Bronchial Carcinoma Therapy Group, et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the bronchial carcinoma therapy group. J Clin Oncol. 2006;24(27):4397–404.

    Article  CAS  PubMed  Google Scholar 

  24. Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer institute of Canada clinical trials group trials. J Clin Oncol. 2008;26(1):54–9.

    Article  CAS  PubMed  Google Scholar 

  25. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97(9):643–55.

    Article  CAS  PubMed  Google Scholar 

  26. Rozensztajn N, Ruppert AM, Lavole A, et al. Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors. Cancer Med. 2014;3(1):61–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Friboulet L, Friboulet KA, Pignon JP, et al. ERCC1 isoform expression and DNA repair in non–small-cell lung cancer. N Engl J Med. 2013;368:1101–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Tanta University, Tanta, Egypt

    Lamiss Mohamed Sad, Samar Galal Younis & Mohamed Mosad Elity

Authors
  1. Lamiss Mohamed Sad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samar Galal Younis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed Mosad Elity
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lamiss Mohamed Sad.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sad, L.M., Younis, S.G. & Elity, M.M. Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer. Med Oncol 31, 58 (2014). https://doi.org/10.1007/s12032-014-0058-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0058-9

Keywords

Search

Navigation